RYTM (Rhythm Pharmaceuticals) Other Gross PPE: $2.9 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RYTM Rhythm Pharmaceuticals Inc RYTM
57 GF Score
Price $112.58
GF Value $120.91
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Rhythm Pharmaceuticals Other Gross PPE?

Rhythm Pharmaceuticals RYTM +0.59% 57 Other Gross PPE is $2.9 Mil as of Jun. 2026. GuruFocus rates RYTM with a GF Score™ of 57/100 and a GF Value™ of $120.91 (Fairly Valued). The stock has 3 warning signs investors should review.

Rhythm Pharmaceuticals's Other Gross PPE for the quarter that ended in Jun. 2026 was $2.9 Mil.

Rhythm Pharmaceuticals's quarterly Other Gross PPE declined from Dec. 2025 ($5.8 Mil) to Mar. 2026 ($4.0 Mil) and declined from Mar. 2026 ($4.0 Mil) to Jun. 2026 ($2.9 Mil).

Rhythm Pharmaceuticals's annual Other Gross PPE increased from Dec. 2023 ($3.5 Mil) to Dec. 2024 ($6.2 Mil) but then declined from Dec. 2024 ($6.2 Mil) to Dec. 2025 ($5.8 Mil).

Rhythm Pharmaceuticals Other Gross PPE Historical Data

* Premium members only.

The historical data trend for Rhythm Pharmaceuticals's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rhythm Pharmaceuticals Other Gross PPE Chart

Rhythm Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Gross PPE
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.23 3.89 3.49 6.18 5.78

Rhythm Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Gross PPE Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.56 3.40 5.78 4.00 2.92
RYTM
57GF Score
Rhythm Pharmaceuticals Inc RYTM
Other Gross PPE is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rhythm Pharmaceuticals Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

Frequently Asked Questions Learn more about Other Gross PPE →
What does a Other Gross PPE of $2.9 Mil mean?
Rhythm Pharmaceuticals (RYTM) has a Other Gross PPE of $2.9 Mil as of Jun. 2026. Other Gross PPE is property, plant and equipment recorded on a company's balance sheet that not otherwise classified. View historical data on Rhythm Pharmaceuticals and its competitors.
Is Rhythm Pharmaceuticals' Other Gross PPE too high?
Rhythm Pharmaceuticals' current Other Gross PPE is $2.9 Mil. Overall, Rhythm Pharmaceuticals has a GF Score™ of 57/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Rhythm Pharmaceuticals' Other Gross PPE compare to MIRM and COGT?
Rhythm Pharmaceuticals' Other Gross PPE of $2.9 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Gross PPE for a Biotechnology company?
A good Other Gross PPE depends on the Biotechnology industry context. However, Other Gross PPE should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Gross PPE mean?
A high Other Gross PPE can signal that a stock is expensive relative to its fundamentals. Other Gross PPE is property, plant and equipment recorded on a company's balance sheet that not otherwise classified. View historical data on Rhythm Pharmaceuticals and its competitors. Rhythm Pharmaceuticals's current Other Gross PPE is $2.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhythm Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Rhythm Pharmaceuticals (RYTM) is currently considered Fairly Valued. The stock's GF Value™ is $120.91, compared to a current price of $112.58 — trading 6.9% below its estimated fair value. The current Other Gross PPE is $2.9 Mil. Rhythm Pharmaceuticals' overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Gross PPE calculated?
Other Gross PPE is calculated from a company's financial statements. For Rhythm Pharmaceuticals (RYTM), the current Other Gross PPE is $2.9 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Rhythm Pharmaceuticals (RYTM) Overvalued in 2026?

Based on GuruFocus' analysis, Rhythm Pharmaceuticals stock appears to be undervalued. The current stock price of $112.58 is trading 6.9% below its estimated GF Value™ of $120.91. GuruFocus considers Rhythm Pharmaceuticals to be Fairly Valued.

Key valuation signals for RYTM:

  • Other Gross PPE: $2.9 Mil
  • GF Value™: $120.91 vs. price of $112.58 (6.9% below fair value)
  • GF Score™: 57/100 with 3 warning signs

No single metric tells the full story. See the RYTM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Rhythm Pharmaceuticals Business Description

Other Exchanges 1RV:Germany
Address 222 Berkeley Street, 12th Floor, Boston, MA, USA, 02116
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
57GF Score

Get the complete analysis for RYTM

Other Gross PPE is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$112.58
Price
$120.91
GF Value